<DOC>
	<DOCNO>NCT02415556</DOCNO>
	<brief_summary>The main purpose study find long-term effect daily administration 40 IU intranasal insulin ( INI ) compare placebo ( sterile saline ) cognition memory people type 2 diabetes mellitus ( DM ) , non-diabetic control 24 week follow-up period 24 week . Four group test : DM group treat INI ; DM group treat placebo ; control group treat INI control group treat placebo . The INI placebo deliver nose . The investigator interested see whether INI improve memory cognition blood flow brain type 2 DM group compare placebo non-diabetic group long-term period .</brief_summary>
	<brief_title>Memory Aid Intranasal Insulin Diabetes ( MemAID )</brief_title>
	<detailed_description>The investigator propose randomize controlled trial determine long-term effect intranasal insulin ( INI ) cognition memory type 2 diabetes ( DM ) non-DM group . The investigator hypothesize : 1 ) INI-treated adult DM good memory function specific cognitive domain faster walk dual task treat placebo control group ; 2 ) Glycemic insulin resistance genetic marker Alzheimer 's disease ( Apolipoprotein E4 [ ApoE4 ] ) may serve predictor positive response INI therapy ; 3 ) INI treatment neither adversely affect systemic glycemic level cardiovascular system cause weight gain . Aim 1 : To determine whether INI-treated type 2 DM adult ) good memory function specific cognitive domain b ) faster dual-task gait speed well daily live function placebo-treated non-DM group . Four group test : 90 DM subject treat insulin ; 90 DM subject treat placebo ; 90 control subject treat INI 90 control subject treat placebo . The investigator conduct randomize , double-blind , placebo-controlled study 180 old adult type 2 DM 180 non-DM control examine whether 40 IU INI daily 24-week period improves : - Specific domains visuospatial attention memory , verbal learning ( primary outcome ) ; - Gait speed dual task ( excellent predictor overall health ) , daily living functionality , depression compare DM group receive sterile saline non-DM group . The non-DM group provide reference INI effect clinical phenotype cognitive decline insulin resistance occur normal age . Aim 2 : To identify phenotype long-term trajectory predict clinically relevant response INI therapy base glycemic control , insulin resistance , endothelial genetic marker . 1 . The investigator determine phenotype predict clinically relevant response INI therapy identify time-dependent trajectory INI effect cognition DM group vs. placebo non-DM group . Clinical predictor base association cognitive function and/or gait demographic , glycemic control , insulin resistance , endothelial genetic ( ApoE4 ) measure . 2 . The investigator evaluate dose-escalating trajectory cognition , gait speed , functionality 24 week therapy 24 week post-treatment dependence above-mentioned factor , determine time point maximum effect reach . INI therapy response define clinically relevant improvement cognitive test gait speed ( continuous variable ) responder vs. non-responders compare placebo within DM non-DM group ( categorical variable ) . 3 . MRI substudy : The investigator explore long-term INI effect regional perfusion , vasodilatation , rest functional connectivity 36 DM 36 non-DM subject pre- post- INI/placebo administration begin end intervention relationship cognitive outcome . Regional perfusion vasodilatation measure pseudo-continuous arterial spin labeling ( PCASL ) MRI 3 Tesla , resting-state functional connectivity quantify low-frequency ( 0.01-0.08 Hz ) fluctuation ( LFF ) whole-brain blood-oxygen-level dependent ( BOLD ) functional Magnetic Resonance Imaging ( fMRI ) . Aim 3 : To determine long-term safety INI vs. placebo regard glycemic control ( fast glucose , hemoglobin A1c [ HbA1c ] , hypoglycemic episode ) , vital sign , body mass . 1 . The investigator obtain measurement fast glucose , insulin , vital sign , body mass baseline , 2-months , 4-months , 6-months follow-up keep weekly log monitor glucose adverse event . 2 . Safety substudy : In first 20 DM patient treat subcutaneous insulin , investigator conduct continuous glucose monitoring ( CGM ) 1 week baseline first week INI placebo treatment evaluate INI effect glycemic control , hypoglycemic episode , body weight . This study may pave way potential treatment and/or cure DM- age-related cognitive decline .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Men woman age 5085 year old Able walk 6 minute Diabetes type 2 ( DM ) group : diagnosis treatment type 2 DM noninsulin oral injectable agent insulin NonDM group similar age range DM group , nondiabetic fasting plasma glucose ( &lt; 126 mg/dL ) hemoglobin A1c ( HbA1c ) ( &lt; 6.5 % ) Participants capable provide informed consent Type 1 DM Intolerance insulin History severe hypoglycemia Participants &gt; 1 asymptomatic and/or symptomatic episode hypoglycemia ( glucose &lt; 70 mg/dL ) finger stick plasma glucose Acute medical condition require either hospitalization surgery within past 6 month ( e.g. , severe hypoglycemia , malignancy , myocardial infarction , stroke ) Severe chronic sinus problem allergies Liver renal failure transplant Dementia ( Mini Mental State Examination [ MMSE ] score â‰¤20 ) Current recreational drug alcohol abuse Morbid obesity ( body mass index [ BMI ] &gt; 45 ) Serious systemic disease would interfere conduction clinical trial Magnetic Resonance Imaging ( MRI ) substudy : claustrophobia implant incompatible 3Tesla MRI</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Intranasal Insulin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Memory</keyword>
	<keyword>Gait</keyword>
	<keyword>Non diabetic older control</keyword>
</DOC>